Novel Biomarkers for Renal Diseases? None for the Moment (but One)

Giorgio Gentile, Giuseppe Remuzzi

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Recent years have witnessed the unprecedented development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, as well as a growing interest in novel single biomarkers and process-specific biomarker panels in human renal diseases. In a scenario currently dominated by kidney biopsy and established biomarkers such as serum creatinine, albuminuria, and proteinuria, novel biomarkers could potentially provide vital diagnostic and prognostic information and help to predict response to treatment in several clinical settings, including acute kidney injury, renal transplant, autosomal dominant polycystic kidney disease, and glomerulopathies. However, it is still uncertain whether and to what extent novel biomarkers will succeed in this difficult task. To date, they have generally failed to provide relevant information over and above what is already granted by established, cheap, and easily available biomarkers such as proteinuria, while the complexity and costs of these technology platforms are an important obstacle to their wide adoption. On the other hand, the successful implementation of anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic biomarker of membranous nephropathy, as well as the huge number of ongoing collaborative efforts worldwide, should induce the nephrology community to be rather optimistic about a potential breakthrough in the management of kidney diseases over the next few decades.

Original languageEnglish
Pages (from-to)655-670
Number of pages16
JournalJournal of Biomolecular Screening
Volume21
Issue number7
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Biomarkers
Kidney
Proteinuria
Phospholipase A2 Receptors
Autosomal Dominant Polycystic Kidney
Membranous Glomerulonephritis
Transplants
Albuminuria
Metabolomics
Nephrology
Biopsy
Kidney Diseases
Genomics
Acute Kidney Injury
Epigenomics
Proteomics
Creatinine
Technology
Costs and Cost Analysis
Antibodies

Keywords

  • acute kidney injury
  • biomarkers
  • chronic kidney disease
  • genomics
  • glomerulopathies
  • kidney transplant
  • metabolomics
  • proteomics
  • review

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmacology
  • Biochemistry
  • Molecular Medicine
  • Biotechnology

Cite this

Novel Biomarkers for Renal Diseases? None for the Moment (but One). / Gentile, Giorgio; Remuzzi, Giuseppe.

In: Journal of Biomolecular Screening, Vol. 21, No. 7, 01.08.2016, p. 655-670.

Research output: Contribution to journalReview article

@article{f9620c292d4a43daae302ea20f730759,
title = "Novel Biomarkers for Renal Diseases? None for the Moment (but One)",
abstract = "Recent years have witnessed the unprecedented development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, as well as a growing interest in novel single biomarkers and process-specific biomarker panels in human renal diseases. In a scenario currently dominated by kidney biopsy and established biomarkers such as serum creatinine, albuminuria, and proteinuria, novel biomarkers could potentially provide vital diagnostic and prognostic information and help to predict response to treatment in several clinical settings, including acute kidney injury, renal transplant, autosomal dominant polycystic kidney disease, and glomerulopathies. However, it is still uncertain whether and to what extent novel biomarkers will succeed in this difficult task. To date, they have generally failed to provide relevant information over and above what is already granted by established, cheap, and easily available biomarkers such as proteinuria, while the complexity and costs of these technology platforms are an important obstacle to their wide adoption. On the other hand, the successful implementation of anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic biomarker of membranous nephropathy, as well as the huge number of ongoing collaborative efforts worldwide, should induce the nephrology community to be rather optimistic about a potential breakthrough in the management of kidney diseases over the next few decades.",
keywords = "acute kidney injury, biomarkers, chronic kidney disease, genomics, glomerulopathies, kidney transplant, metabolomics, proteomics, review",
author = "Giorgio Gentile and Giuseppe Remuzzi",
year = "2016",
month = "8",
day = "1",
doi = "10.1177/1087057116629916",
language = "English",
volume = "21",
pages = "655--670",
journal = "Journal of Biomolecular Screening",
issn = "1087-0571",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Novel Biomarkers for Renal Diseases? None for the Moment (but One)

AU - Gentile, Giorgio

AU - Remuzzi, Giuseppe

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Recent years have witnessed the unprecedented development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, as well as a growing interest in novel single biomarkers and process-specific biomarker panels in human renal diseases. In a scenario currently dominated by kidney biopsy and established biomarkers such as serum creatinine, albuminuria, and proteinuria, novel biomarkers could potentially provide vital diagnostic and prognostic information and help to predict response to treatment in several clinical settings, including acute kidney injury, renal transplant, autosomal dominant polycystic kidney disease, and glomerulopathies. However, it is still uncertain whether and to what extent novel biomarkers will succeed in this difficult task. To date, they have generally failed to provide relevant information over and above what is already granted by established, cheap, and easily available biomarkers such as proteinuria, while the complexity and costs of these technology platforms are an important obstacle to their wide adoption. On the other hand, the successful implementation of anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic biomarker of membranous nephropathy, as well as the huge number of ongoing collaborative efforts worldwide, should induce the nephrology community to be rather optimistic about a potential breakthrough in the management of kidney diseases over the next few decades.

AB - Recent years have witnessed the unprecedented development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, as well as a growing interest in novel single biomarkers and process-specific biomarker panels in human renal diseases. In a scenario currently dominated by kidney biopsy and established biomarkers such as serum creatinine, albuminuria, and proteinuria, novel biomarkers could potentially provide vital diagnostic and prognostic information and help to predict response to treatment in several clinical settings, including acute kidney injury, renal transplant, autosomal dominant polycystic kidney disease, and glomerulopathies. However, it is still uncertain whether and to what extent novel biomarkers will succeed in this difficult task. To date, they have generally failed to provide relevant information over and above what is already granted by established, cheap, and easily available biomarkers such as proteinuria, while the complexity and costs of these technology platforms are an important obstacle to their wide adoption. On the other hand, the successful implementation of anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic biomarker of membranous nephropathy, as well as the huge number of ongoing collaborative efforts worldwide, should induce the nephrology community to be rather optimistic about a potential breakthrough in the management of kidney diseases over the next few decades.

KW - acute kidney injury

KW - biomarkers

KW - chronic kidney disease

KW - genomics

KW - glomerulopathies

KW - kidney transplant

KW - metabolomics

KW - proteomics

KW - review

UR - http://www.scopus.com/inward/record.url?scp=84979289624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979289624&partnerID=8YFLogxK

U2 - 10.1177/1087057116629916

DO - 10.1177/1087057116629916

M3 - Review article

VL - 21

SP - 655

EP - 670

JO - Journal of Biomolecular Screening

JF - Journal of Biomolecular Screening

SN - 1087-0571

IS - 7

ER -